Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma
Authors: Gustavo Schvartsman, Kristen Perez, Gagan Sood, Riham Katkhuda, Hussein Tawbi
Journal: Annals of Internal Medicine (2017)

Letters5 September 2017Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With MelanomaGustavo Schvartsman, MD, Kristen Perez, PA-C, Gagan Sood, MD, Riham Katkhuda, MD, and Hussein Tawbi, MD, PhDGustavo Schvartsman, MDFrom The University of Texas MD Anderson Cancer Center, Houston, Texas; Baylor College of Medicine, Houston, Texas; The University of Texas MD Anderson Cancer Center, Houston, Texas., Kristen Perez, PA-CFrom The University of Texas MD Anderson Cancer Center, Houston, Texas; Baylor College of Medicine, Houston, Texas; The University of Texas MD Anderson Cancer Center, Houston, Texas., Gagan Sood, MDFrom The University of Texas MD Anderson Cancer Center, Houston, Texas; Baylor College of Medicine, Houston, Texas; The University of Texas MD Anderson Cancer Center, Houston, Texas., Riham Katkhuda, MDFrom The University of Texas MD Anderson Cancer Center, Houston, Texas; Baylor College of Medicine, Houston, Texas; The University of Texas MD Anderson Cancer Center, Houston, Texas., and Hussein Tawbi, MD, PhDFrom The University of Texas MD Anderson Cancer Center, Houston, Texas; Baylor College of Medicine, Houston, Texas; The University of Texas MD Anderson Cancer Center, Houston, Texas.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0187 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Immune checkpoint inhibitors are frequently used to treat patients with metastatic melanoma. However, all of the clinical trials for these drugs have excluded patients with a history of autoimmune disease and those receiving immunosuppressive therapy for another condition because of concerns that they might reactivate autoimmune disease or interfere with immune suppression. Therefore, not enough is known about how such patients respond to checkpoint inhibitors. For example, recipients of solid organ transplants who undergo long-term immune suppression have a higher incidence of cancer, including melanoma (1). However, few reports of checkpoint inhibitor therapy in this population are available (2).... References1. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681-91. [PMID: 12711744] CrossrefMedlineGoogle Scholar2. Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904-11. [PMID: 28241095] doi:10.1002/cncr.30642 CrossrefMedlineGoogle Scholar3. Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39:1075-84. [PMID: 26034866] doi:10.1097/PAS.0000000000000453 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From The University of Texas MD Anderson Cancer Center, Houston, Texas; Baylor College of Medicine, Houston, Texas; The University of Texas MD Anderson Cancer Center, Houston, Texas.Acknowledgment: The authors thank the patient and his family.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0187.Financial Support: No external funding.This article was published at Annals.org on 1 August 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImmunotherapy and Hepatocellular CarcinomaImmune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant OncologyImmunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysisImmune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literatureImmune checkpoint blockade for organ-transplant recipients with cancer: A reviewImmune checkpoint inhibitors for solid organ transplant recipients: clinical updatesDer Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-AbwägungImmunotherapy in liver transplantation for hepatocellular carcinoma: Pros and consAn analysis report on the application of immune checkpoint inhibitors after liver transplantationApplication of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic ReviewImmunotherapy after liver transplantation: Where are we now?Immunotherapy after liver transplantation: Where are we now?Skin Cancers and Lung TransplantTransplant Oncology in Primary and Metastatic Liver TumorsImmune Checkpoint Inhibitors in Transplantation—A Case Series and Comprehensive Review of Current KnowledgeImmuno-oncology for Hepatocellular CarcinomaImmune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic reviewThe Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of LiteratureCutaneous squamous cell carcinoma in the organ transplant recipientSystematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant PatientsSkin cancer in transplant recipients: Scientific retreat of the international immunosuppression and transplant skin cancer collaborative and skin care in organ transplant patients—EuropeCheckpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literatureLiver graft rejection following immune checkpoint inhibitors treatment: a reviewImmunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejectionImmune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?Immune checkpoint inhibitors in the management of malignancies in transplant recipientsAnti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionGraft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipientsImmune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical reviewLiver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature ResearchCancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients 5 September 2017Volume 167, Issue 5Page: 361-362KeywordsAlanine aminotransferaseBiopsyHepatitisInflammationLiverMelanomaNecrosisSerum glutamic oxaloacetic transaminaseSteroidsViral load ePublished: 1 August 2017 Issue Published: 5 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...